Biljana Naumovic of Johnson & Johnson discusses the unique fashion show and how it's raising awareness for prostate cancer. Biljana Naumovic, president of US Oncology Solid Tumor at Johnson & Johnson, ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.

Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease. PE: The phase Ib trial demonstrated improvements in histology, symptoms, ...